Adults with type 2 diabetes, together with diet and exercise, to improve blood sugar.
Sources last read
Brand guide · Semaglutide
What is Ozempic?
Ozempic is a weekly semaglutide injection for type 2 diabetes. Its label also covers certain heart and kidney risks.
Source for this answer
Source: Current FDA label, checked 2026-08-12
Source: Current FDA label, checked 2026-08-12
Explore Ozempic
Approved uses
What is Ozempic approved to treat?
Adults with type 2 diabetes and established heart or blood vessel disease. This use lowers the risk of heart attack, stroke and heart-related death.
Adults with type 2 diabetes and chronic kidney disease, to lower the risk of kidney failure and heart-related death.
The product itself
Available forms and strengths
Single-patient-use pen, 2 mg per 3 mL
4 doses
Single-patient-use pen, 4 mg per 3 mL
4 doses
Single-patient-use pen, 8 mg per 3 mL
4 doses
Single-dose prefilled syringe
1 dose
Key product facts
What matters first
- Medicine
- Semaglutide
- How often
- Once weekly, on the same day each week, at any time of day, with or without meals
- Starting dose
- 0.25 mg
- Highest labeled dose
- 2 mg
Novo Nordisk makes Ozempic under NDA 209637. Ozempic comes as a shot under the skin.
Same medicine, different label
How is Ozempic different from Wegovy?
Ozempic and Wegovy both contain semaglutide. Ozempic is approved for type 2 diabetes. Wegovy is approved for weight-related care. Their dose plans are not the same.
Read the Wegovy overview- Ozempic (semaglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-09-13FDA label
- Drugs@FDA approval history — NDA 209637, Ozempic (semaglutide) injectionretrieved 2026-08-12FDA label
- FDA approval letter, NDA 209637 — Ozempic (semaglutide) injection, glycemic control in adults with type 2 diabetesretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 209637/S-003 — Ozempic cardiovascular event risk reduction in type 2 diabetes with established cardiovascular disease (SUSTAIN 6)retrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 209637/S-025 — Ozempic for reducing sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney diseaseretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 209637/S-009 — addition of a third Ozempic maintenance dose, 2 mg once weeklyretrieved 2026-08-12FDA label